HUE025723T2 - Dialkoxikinazolin-származékok mint KDR inhibitorok - Google Patents

Dialkoxikinazolin-származékok mint KDR inhibitorok Download PDF

Info

Publication number
HUE025723T2
HUE025723T2 HUE09743783A HUE09743783A HUE025723T2 HU E025723 T2 HUE025723 T2 HU E025723T2 HU E09743783 A HUE09743783 A HU E09743783A HU E09743783 A HUE09743783 A HU E09743783A HU E025723 T2 HUE025723 T2 HU E025723T2
Authority
HU
Hungary
Prior art keywords
alkyl
compound
aryl
heteroaryl
rti
Prior art date
Application number
HUE09743783A
Other languages
English (en)
Inventor
Wei-Guo Su
Weihan Zhang
Xiaoqiang Yan
Yumin Cui
Yongxin Ren
Jifeng Duan
Original Assignee
Hutchison Medipharma Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Entpr Ltd filed Critical Hutchison Medipharma Entpr Ltd
Publication of HUE025723T2 publication Critical patent/HUE025723T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (3)

  1. Szabadalmi igénypontok L ügy alább; képied vegyidet:
    * a képletben Rj.. M.2? %, íip R* és Räe mfodegvskértek jelentése egymástól függetlenül 11, halogén, nitro, amine, ciano, hklroxik l-IO szénatomot tartalmazó alkil, 2-10 szénatomot tartabnaml síken 11, 2-1Ö szénatomot tartalmazó alkmtl, 6 szénatomot tartalmazó monocMusos, 10 szénatomot tartalmazó bicikfosos vágj·· 34 szénatomot tartalmazó trieik Insos árit, .1-12 szénatomot tartalmazó cikloaikil, 3-S-lagú moaodkíosos, k- i 2~tagé btcíkittsos vagy 11'14-tsgó trieiklusos· heierodkloalklh Jt-S-tagiV monoeikhtsos, 8- )2-tsg{j. bictklusos vagy 11 *i4*tagó trt-elklusos heteroaril, aikoxi, afkiltto, alktikarbonii, karboxi, aikoxikarbontf, ammokarbonri or aminoszulfom!; Il ï 6s R, mindegyikének jelentése alkod;, kijelentése alkil; jelentése rtSlOJNI’y^, ahol RB és % mindegyikének jelentése egymástól foggetforfoi H,; alkil, a&eml, alklnll, adt, dkfoaidl, heleroeskloalksl vagy hetmtaril, vagy Rs és együtt 3 - S-tagn, 1-3 hétéro-atomot tartalmazó gyűrűt képeznek azzal a. oíRogtfoaíonnnah amelyhez kapcsolódnak; X jelentése O, és Z jelentése· X: ahol az alkil, álként!, síkból, dkloalkll, heteróeikloaÉíi, aril, heteroaril és alkod csoportok- mindegyike magába .foglal helveítesltetlee vagy hehettedioit csoportokat, és a. helyettesítők, a következük közül vannak megválásává· halogén, htátoxtl, amino, ctano, -mrro, merkapto, alkoxikarborsii, amidé, ksrboxt,afkánsad&all, alkilkarbonil. karban) tdo, karbamlt, karhoz ti, ttonretéo,· tsociaPáixt, szalfonamido, alkil, alkenti, alklnil slkoxs, aril, heteroaril, cikloalkH és betetodkloslkil,
  2. 2, Az 1 igénypont szerinti vegytllet, áltól az alkil, atkeoll, aikmii, dktóalfell. heteroelklfodkil, aril, hetentaril és alkoxi «sopoaek. mindegyike helyetted teilen, .3. Áz 1, igénypont .szerinti· vegyitlei, ahol Rfi jelentése nreíth 4 Az I, Igénypert szerinti vegytlet, ahol Ra és % mindegyikének jelentése egymástól riggeíienill fi, alkil vagy clkloalkE 5. A 4. igénypont szerinti vegyüld, ahol Rg jelentése H ás Rä, jelentése metik é, A 4. Igénypont szerinti vegyidét, -aholR.^ és :R4 mindegyikének jelentése metoxt. 7. ,½ ?. igánypordsaemá yegy öletek kWf a» sláfeEiak valamelyike:
    képletn vegySkt.
  3. 9. Gyógyászati készítmény amely magába foglal egy í. igénypont szmtät vegyületsí és egy győgyásza- tilag: s-ífogiAalö :'í:>íd->aóai!yag;>t i(í< Egy L igénypont: szerinti vsgyülst érkèpxÔdëssei {mgh^sésk} kapcsolatos; rendellenesség: kezelésére való alkalmazásra, íl.> A 3Ö. igénypont szerinti vegyidet, a&amp;ol az érképzédésset (agglogesézis) kapcsolatos rendellenesség rák, MSs korra! Összetlíggő macnla-degenerácio vagy krónikás gyniladlisos feeíegság;,
HUE09743783A 2008-05-09 2009-05-08 Dialkoxikinazolin-származékok mint KDR inhibitorok HUE025723T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/118,019 US7829574B2 (en) 2008-05-09 2008-05-09 Substituted quinazoline compounds and their use in treating angiogenesis-related diseases

Publications (1)

Publication Number Publication Date
HUE025723T2 true HUE025723T2 (hu) 2016-04-28

Family

ID=41265455

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE09743783A HUE025723T2 (hu) 2008-05-09 2009-05-08 Dialkoxikinazolin-származékok mint KDR inhibitorok

Country Status (21)

Country Link
US (3) US7829574B2 (hu)
EP (1) EP2297115B1 (hu)
JP (2) JP5856842B2 (hu)
KR (2) KR20160045925A (hu)
AU (1) AU2009244130B2 (hu)
BR (1) BRPI0908675B1 (hu)
CA (1) CA2723148C (hu)
CY (1) CY1117222T1 (hu)
DK (1) DK2297115T3 (hu)
ES (1) ES2550245T3 (hu)
HR (1) HRP20150954T1 (hu)
HU (1) HUE025723T2 (hu)
MX (2) MX2010012168A (hu)
MY (1) MY155566A (hu)
NZ (1) NZ588900A (hu)
PL (1) PL2297115T3 (hu)
PT (1) PT2297115E (hu)
RU (1) RU2506261C2 (hu)
SI (1) SI2297115T1 (hu)
TW (1) TWI458724B (hu)
WO (1) WO2009137797A2 (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
PT2396307E (pt) * 2009-02-11 2015-02-04 Merck Patent Gmbh Novas carboxamidas azaheterocíclicas de amino
EP3575288B1 (en) 2009-09-03 2021-10-27 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
CN105461702A (zh) * 2014-09-10 2016-04-06 和记黄埔医药（上海）有限公司 6-(6,7-二甲氧基喹唑啉-4-基氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型
MX2018004109A (es) 2015-10-05 2018-09-27 Univ Columbia Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
WO2017189483A1 (en) 2016-04-25 2017-11-02 The Johns Hopkins University Znt8 assays for drug development and pharmaceutical compositions
US11892457B2 (en) 2017-07-12 2024-02-06 The Johns Hopkins University Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
CN116987069A (zh) * 2018-03-30 2023-11-03 杭州领业医药科技有限公司 呋喹替尼的共晶、其制备方法、组合物和用途
CN111184698A (zh) * 2018-11-15 2020-05-22 和记黄埔医药（上海）有限公司 呋喹替尼制剂及其应用
CN110898065A (zh) * 2019-11-25 2020-03-24 南通大学 呋喹替尼或其盐在制备治疗脉络膜新生血管药物中的用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US6235741B1 (en) 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
ES2351699T3 (es) * 1999-02-10 2011-02-09 Astrazeneca Ab Derivados de quinazolina como inhibidores de la angiogénesis e intermedios de los mismos.
US6943161B2 (en) 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
DE10009267A1 (de) * 2000-02-26 2001-08-30 Goedecke Ag Verfahren zur einfachen Herstellung von (3-Chlor-4-fluor-phenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazolin-4-yl]-amin bzw. (3-Chlor-4-fluor-phenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazolin-4-yl]-amin
AR035851A1 (es) * 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
WO2002030926A1 (en) * 2000-10-13 2002-04-18 Astrazeneca Ab Quinazoline derivatives
US6849625B2 (en) * 2000-10-13 2005-02-01 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
US20040092750A1 (en) 2001-03-01 2004-05-13 Tomoyuki Hasegawa 2-methylindole-4-acetic acid, process for producing the same, and process for producing intermediate therefor
AU2002347336A1 (en) * 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
CN1678321A (zh) 2002-07-29 2005-10-05 里格尔药品股份有限公司 用2,4－嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
CN1845924A (zh) * 2003-07-02 2006-10-11 弗·哈夫曼-拉罗切有限公司 芳基胺取代的喹唑啉酮化合物
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
GB0318423D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
CA2551508C (en) 2003-12-23 2011-08-09 Pfizer Inc. Novel quinoline derivatives
WO2005097137A2 (en) * 2004-03-31 2005-10-20 The Scripps Research Institute Advanced quinazoline based protein kinase inhibitors
WO2005115145A2 (en) 2004-05-20 2005-12-08 Wyeth Quinone substituted quinazoline and quinoline kinase inhibitors
US20080268460A1 (en) * 2004-05-20 2008-10-30 Wyeth Assays to Identify Irreversibly Binding Inhibitors of Receptor Tyrosine Kinases
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
WO2006071079A1 (en) 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
WO2006138304A2 (en) 2005-06-14 2006-12-28 Taigen Biotechnology Pyrimidine compounds
JP2009518382A (ja) 2005-12-05 2009-05-07 ファイザー・プロダクツ・インク Ｖｅｇｆ−ｒ阻害剤を調製する方法
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
GB0604937D0 (en) * 2006-03-10 2006-04-19 Novartis Ag Organic compounds
JP2010505386A (ja) 2006-05-15 2010-02-25 セネックス バイオテクノロジー，インク． Ｃｄｋｉ経路阻害剤の同定
TW200922590A (en) * 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases

Also Published As

Publication number Publication date
RU2506261C2 (ru) 2014-02-10
ES2550245T3 (es) 2015-11-05
JP2014177499A (ja) 2014-09-25
TW201002694A (en) 2010-01-16
US20110015213A1 (en) 2011-01-20
WO2009137797A2 (en) 2009-11-12
HRP20150954T1 (hr) 2015-10-09
MX2014001023A (es) 2014-05-22
US8497372B2 (en) 2013-07-30
EP2297115B1 (en) 2015-07-22
AU2009244130B2 (en) 2012-11-01
CY1117222T1 (el) 2017-04-05
AU2009244130A1 (en) 2009-11-12
RU2010150345A (ru) 2012-06-20
BRPI0908675A2 (pt) 2015-08-04
PL2297115T3 (pl) 2015-12-31
CA2723148C (en) 2015-01-20
MY155566A (en) 2015-10-30
WO2009137797A3 (en) 2010-02-25
PT2297115E (pt) 2015-10-26
US20120238572A1 (en) 2012-09-20
TWI458724B (zh) 2014-11-01
DK2297115T3 (en) 2015-08-10
CA2723148A1 (en) 2009-11-12
SI2297115T1 (sl) 2015-10-30
MX340021B (es) 2016-06-22
JP2011519956A (ja) 2011-07-14
EP2297115A2 (en) 2011-03-23
BRPI0908675B1 (pt) 2022-01-25
KR20160045925A (ko) 2016-04-27
MX2010012168A (es) 2011-02-18
US7829574B2 (en) 2010-11-09
US20090281130A1 (en) 2009-11-12
US8212033B2 (en) 2012-07-03
EP2297115A4 (en) 2012-03-14
KR20110013381A (ko) 2011-02-09
JP5856842B2 (ja) 2016-02-10
NZ588900A (en) 2012-12-21
KR101686679B1 (ko) 2016-12-14

Similar Documents

Publication Publication Date Title
DK2297115T3 (en) DIALCOXYQUINAZOLINE DERIVATIVES AS KDR INHIBITORS
TWI484960B (zh) 嘧啶衍生物
TWI642667B (zh) 吡啶並嘧啶類衍生物、其製備方法及其在醫藥上的應用
EP2318378B1 (en) Quinazoline derivatives
BRPI0805826B1 (pt) compostos espiro-substituídos, composição farmacêutica e uso
CN106478502B (zh) 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
WO2010025138A2 (en) Pyrimidine compounds
US20060110467A1 (en) Cancer chemotherapy
JPS63264580A (ja) ３−（２−ハロアルキル）−１，４−オキサチインおよび２−（２−ハロアルキル）−１，４−ジチイン
AU2008240084B2 (en) Pyrimidine derivatives
JP5561648B2 (ja) ロダシアニン誘導体及びリーシュマニア感染症治療用医薬組成物
TW202317572A (zh) 雜環大環化合物及其醫藥用途
KR100621192B1 (ko) 무스카린 수용체 작용물질로서 작용하는1,2,3,4-테트라하이드로피리미디닐-1,2,4-옥사다이아졸유도체와 이의 제조방법